Amgen

BeiGene and Amgen announced a global strategic oncology collaboration for the commercialization and development of three Amgen drugs in China and joint development of 20 pipeline assets. Amgen will purchase a 20.5% stake in BeiGene for approximately $2.7 billion.

Amgen broke ground on a new next-generation biomanufacturing plant at its West Greenwich, Rhode Island campus. The company expects to invest up to $200 million in the 120,000 square foot facility, which will use innovative technologies to produce medicines for U.S. and global markets.

Amgen announced plans to build a new next-generation biomanufacturing plant at its campus in West Greenwich, Rhode Island. The plant is expected to create approximately 150 manufacturing jobs and 200 construction and validation jobs.

Amgen entered into a six-year Sourcing and Supply Agreement with DaVita Inc. to supply EPOGEN and Aranesp for dialysis services in the United States and Puerto Rico, covering at least 90% of DaVita's annual requirements.